SIRT6

Across TCGA pan-cancer cohorts, SIRT6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SIRT6 data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher SIRT6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIRT6 expression acts as an unfavorable survival marker.

BLCA, COAD, and UCEC are the cancer types where SIRT6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.117	0.720	<.001	36	view →
COAD	OS	Median	All	0.183	0.806	.004	21	view →
UCEC	OS	Median	III,IV	0.061	0.588	.018	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
CESC	OS	Median	All	0.089	0.585	.025	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUAD	DFS	Median	All	0.049	0.814	<.001	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SIRT6–BLCA (OS)

Open the BLCA breakdown →